What is PAH Disease? Understanding Pulmonary Arterial Hypertension

Pulmonary hypertension is a serious condition affecting the arteries in your lungs and the right side of your heart. When these blood vessels become compromised, blood flow becomes restricted, leading to increased blood pressure within the lungs. This condition is known as pulmonary hypertension. One specific and critical type of pulmonary hypertension is called pulmonary arterial hypertension, or PAH. Understanding what PAH disease is, its symptoms, causes, and risk factors is crucial for early detection and management.

What is Pulmonary Arterial Hypertension (PAH)?

Pulmonary arterial hypertension (PAH) is a specific form of pulmonary hypertension where the small arteries in your lungs, known as the pulmonary arteries, become narrowed, blocked, or even destroyed. This damage makes it harder for blood to flow through your lungs. As a result, the blood pressure in these arteries rises significantly.

Think of your lungs’ blood vessels like a network of roads. In PAH, these roads become congested or damaged. This congestion forces your heart, specifically the right side, to work much harder to pump blood through the lungs. Over time, this extra strain weakens the heart muscle, potentially leading to heart failure.

While there is currently no cure for PAH, effective treatments are available. These treatments aim to alleviate symptoms, improve your quality of life, and potentially extend life expectancy. Early diagnosis and intervention are key to managing PAH effectively.

Alt text: Illustration depicting blood flow through healthy and pulmonary hypertensive lungs, highlighting narrowed pulmonary arteries restricting blood flow.

Symptoms of PAH

The symptoms of PAH can be subtle at first and often develop slowly over months or even years. This gradual onset can make PAH difficult to recognize in its early stages. As the disease progresses, symptoms tend to become more noticeable and impactful.

Common symptoms of PAH include:

Shortness of breath: This is often the first and most common symptom. Initially, it may only occur during physical activity, but as PAH worsens, shortness of breath can happen even at rest.
Cyanosis (Blue or gray skin): Low oxygen levels in the blood can cause a bluish tint to the skin, particularly around the lips and fingertips. This discoloration may be more or less visible depending on an individual’s skin tone.
Chest pain or pressure: Discomfort in the chest area can occur due to the increased strain on the heart.
Dizziness or fainting: Reduced blood flow can lead to lightheadedness or fainting spells, especially during exertion.
Palpitations (Fast pulse or pounding heartbeat): The heart may beat faster or feel like it’s pounding as it tries to compensate for the increased pressure in the lungs.
Fatigue: Persistent tiredness and lack of energy are common symptoms.
Edema (Swelling in ankles, legs, and abdomen): Fluid retention can cause swelling in the lower extremities and abdominal area.

It’s important to note that while shortness of breath is a hallmark symptom of PAH, it can also be caused by many other conditions, such as asthma or lung diseases. Therefore, if you experience persistent shortness of breath or any of the symptoms mentioned above, it is crucial to consult a healthcare professional for an accurate diagnosis.

Causes of PAH

To understand the causes of PAH, it’s helpful to visualize the heart’s structure and function. The heart has four chambers: two upper chambers (atria) and two lower chambers (ventricles). The right ventricle is responsible for pumping blood to the lungs through the pulmonary artery to pick up oxygen.

Alt text: Diagram illustrating the chambers and valves of a human heart, emphasizing the right ventricle and pulmonary artery’s role in blood flow to the lungs.

In healthy lungs, blood flows easily through the pulmonary arteries, capillaries, and veins to the left side of the heart. However, in PAH, changes occur in the cells lining the pulmonary arteries. These changes can lead to:

Narrowing: The arteries become constricted, reducing the space for blood to flow.
Stiffening: The artery walls lose their flexibility, making it harder for them to expand and accommodate blood flow.
Swelling: Inflammation and fluid buildup can thicken the artery walls.
Thickening: The walls of the arteries themselves can become thicker, further obstructing blood flow.

These changes impede blood flow through the lungs, resulting in increased pressure and PAH.

PAH falls under Group 1 of the World Health Organization’s (WHO) classification of pulmonary hypertension. Group 1, specifically PAH, has several subcategories based on the underlying cause:

Group 1: Pulmonary Arterial Hypertension (PAH) Causes

Idiopathic PAH: In many cases, the cause of PAH is unknown. This is referred to as idiopathic pulmonary arterial hypertension.
Heritable PAH: Genetic mutations passed down through families can cause heritable pulmonary arterial hypertension.
Drug- and toxin-induced PAH: Certain medications and illegal drugs, such as methamphetamine and some diet drugs, have been linked to PAH.
PAH associated with other conditions: PAH can occur in association with other medical conditions, including:
- Congenital heart defects: Heart problems present at birth.
- Connective tissue diseases: Such as scleroderma and lupus.
- Chronic liver disease: Like cirrhosis.

Other Groups of Pulmonary Hypertension

While this article focuses on PAH (Group 1), it’s important to understand that pulmonary hypertension can be caused by other factors, categorized into Groups 2 through 5:

Group 2: Pulmonary hypertension due to left heart disease: Conditions like left heart failure and mitral or aortic valve disease are the most common cause of pulmonary hypertension overall.
Group 3: Pulmonary hypertension due to lung diseases: Lung conditions like COPD, pulmonary fibrosis, and sleep apnea can lead to pulmonary hypertension.
Group 4: Pulmonary hypertension due to chronic blood clots: Chronic pulmonary embolism or blockages in the pulmonary arteries can cause this form.
Group 5: Pulmonary hypertension with unclear or multifactorial mechanisms: This group includes PAH associated with blood disorders, inflammatory disorders, metabolic disorders, and kidney disease.

Understanding these different groups is important for diagnosis and treatment, although this article primarily addresses PAH (Group 1).

Risk Factors for PAH

While anyone can develop PAH, certain factors can increase the risk:

Age: PAH is more commonly diagnosed in adults between 30 and 60 years old. The risk of idiopathic PAH increases with age.
Family history: Having a family history of pulmonary hypertension, particularly PAH, increases your risk, especially for heritable forms.
Overweight or obesity: Excess weight is associated with a higher risk.
Smoking: Smoking damages blood vessels and increases the risk of various cardiovascular conditions, including pulmonary hypertension.
Blood-clotting disorders: Conditions that increase the risk of blood clots, or a family history of blood clots, can raise PAH risk.
Asbestos exposure: Exposure to asbestos is a known risk factor for lung diseases and can also increase the risk of pulmonary hypertension.
Congenital heart disease: Heart defects present at birth are a significant risk factor.
High altitude living: Long-term residence at high altitudes can increase the risk in susceptible individuals.
Certain medications and drugs: As mentioned earlier, some drugs can induce PAH.

Complications of PAH

If left untreated or poorly managed, PAH can lead to serious and life-threatening complications:

Cor Pulmonale (Right-sided heart failure): This is a major complication where the right ventricle enlarges and weakens due to the increased workload of pumping against high pressure in the pulmonary arteries. Eventually, the right heart fails.
Blood clots (Pulmonary thrombosis): PAH increases the risk of blood clots forming in the small lung arteries, further obstructing blood flow.
Arrhythmias (Irregular heartbeats): PAH can disrupt the heart’s electrical system, leading to abnormal heart rhythms that can be dangerous.
Pulmonary hemorrhage (Bleeding in the lungs): PAH can cause life-threatening bleeding into the lungs and coughing up blood.
Pregnancy complications: PAH poses significant risks to both the mother and the developing baby during pregnancy and is often life-threatening in this context.

Understanding what PAH disease is, including its symptoms, causes, and potential complications, is the first step towards seeking timely diagnosis and appropriate management. If you suspect you may have symptoms of PAH, consult your doctor promptly.

By Mayo Clinic Staff

Pulmonary hypertension care at Mayo Clinic

Diagnosis & treatment

July 28, 2023

References

Pulmonary hypertension — High blood pressure in the heart-to-lung system. American Heart Association. https://www.heart.org/en/health-topics/high-blood-pressure/the-facts-about-high-blood-pressure/pulmonary-hypertension-high-blood-pressure-in-the-heart-to-lung-system. Accessed May 10, 2023.
Pulmonary hypertension. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/pulmonary-hypertension. Accessed May 10, 2023.
Klinger JR, et al. Therapy for pulmonary arterial hypertension in adults: Update of the CHEST guideline and expert panel report. Chest. 2019; doi:10.1016/j.chest.2018.11.030.
AskMayoExpert. Pulmonary hypertension (adult). Mayo Clinic; 2022.
Rubin LJ, et al. Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults. https://www.uptodate.com/contents/search. Accessed Nov. 19, 2022.
Hopkins W, et al. Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy. https://www.uptodate.com/contents/search. Accessed Nov. 19, 2022.
Fuster V, et al., eds. Pulmonary hypertension. In: Fuster and Hurst’s the Heart. 15th ed. McGraw Hill; 2022. https://accessmedicine.mhmedical.com. Accessed Nov. 19, 2022.
Ami TR. Allscripts EPSi. Mayo Clinic. Dec. 21, 2022.
Ferri FF. Pulmonary hypertension. In: Ferri’s Clinical Advisor 2023. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 19, 2022.
Connolly HM. Evaluation and prognosis of Eisenmenger syndrome. https://www.uptodate.com/contents/search. Accessed Nov. 19, 2022.
Olson EJ (expert opinion). Mayo Clinic. Jan. 24, 2023.
Simonneau G, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. The European Respiratory Journal. 2019; doi:10.1183/13993003.01913-2018.
Gelzinis TA. Pulmonary hypertension in 2021: Part I — definition, classification, pathophysiology, and presentation. Journal of Cardiothoracic and Vascular Anesthesia. 2021; doi:10.1053/j.jvca.2021.06.036.
Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022; doi:10.1093/eurheartj/ehac237.
Highland KB, et al. Development of the pulmonary hypertension functional classification self‑report: A patient version adapted from the World Health Organization functional classification measure. Health and Quality of Life Outcomes. 2021; doi:10.1186/s12955-021-01782-0.
Mankad R (expert opinion). Mayo Clinic. Feb. 7, 2023.
Frantz RP (expert opinion). Mayo Clinic. May 3, 2023.